MiPT
Methylisopropyltryptamine, also known as N-methyl-N-isopropyltryptamine, is a psychedelic drug of the tryptamine family related to other psychedelics like dimethyltryptamine and diisopropyltryptamine. It is taken orally.
The drug acts as a serotonin receptor modulator, including as an agonist of the serotonin 5-HT2A receptor. Derivatives of MiPT include 4-HO-MiPT and 5-MeO-MiPT.
MiPT was first described by David Repke and colleagues in 1981. It was subsequently evaluated and described in Alexander Shulgin's 1997 book TiHKAL. MiPT was encountered as a novel designer drug by 2005.
Use and effects
In his book TiHKAL, Alexander Shulgin lists MiPT's dose as 10 to 25mg orally and its duration as 3 to 4hours. A dose of 20mg by insufflation was also reported. Its onset orally was reported to be 30minutes and peak effects occurred at 1hour. Conversely, its onset via insufflation was said to be immediate or less than 1minute. Oral doses of up to 20mg were described as being relatively mild in their effects. MiPT is notable in being the most potent of the simple N,''N''-dialkyltryptamines, at least via oral administration.The effects of MiPT have been reported to include feeling "definitely psychedelic", being very "heady", effects on thoughts that were typically psychedelic, enhancement of visual field such as brighter colors and more clearly defined objects, vision tinted orange as if there was an orange overlay, an almost total absence of any other visual effects, auditory effects such as enhanced sound discrimination, hearing and skin being more sensitive, and minor sensory changes in general. It was said to emphasize "psychedelic" effects over "hallucinogenic" effects. Other effects included feeling good, excitement, stimulation, feeling alert, restlessness, and trailing insomnia for 6 to 8hours. Physical effects included pupil dilation, dizziness, dry mouth, and muscle tension.